Welcome to our dedicated page for EyePoint SEC filings (Ticker: EYPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EyePoint, Inc.'s SEC filings document its business as a clinical-stage retinal-disease therapeutics company and record formal disclosures around DURAVYU, its investigational vorolanib intravitreal insert using Durasert E sustained-delivery technology. Form 8-K reports cover operating results, financial condition, cash resources, clinical-development updates for wet AMD and DME, investor presentations, and other material company events.
The company's proxy materials disclose governance, executive compensation, equity awards, shareholder voting matters, and board-related information. Additional filings record Nasdaq-listed common stock information, Regulation FD disclosures, forward-looking risk language, and legal-proceeding disclosures related to public statements about DURAVYU and its clinical results.
EyePoint, Inc. Schedule 13G reports that Commodore Capital and related filers beneficially own 4,250,000 shares of EyePoint common stock as of May 27, 2026. The filing states this represents 5.1% of the class using 83,841,298 shares outstanding as of May 1, 2026.
The report clarifies the Firm is the investment manager to Commodore Capital Master LP and that Michael Kramarz and Robert Egen Atkinson are managing partners exercising investment discretion. The filing is a joint statement and includes a signed Joint Filing Agreement.
EyePoint, Inc. Chief Financial Officer George Elston reported routine equity compensation activity involving common stock and restricted stock units. He exercised 7,500 restricted stock units into 7,500 shares of common stock. Of these, 3,627 shares were withheld by EyePoint to cover tax obligations, and no shares were sold in the market.
Following these transactions, Elston holds 91,691 shares of common stock directly. In addition, 30,000 shares of common stock are held indirectly through a family trust for the benefit of his children, for which he disclaims beneficial ownership.
Paradigm BioCapital Advisors and related reporting persons filed Amendment No. 1 to a Schedule 13G/A reporting their beneficial ownership in EyePoint, Inc. The filing lists Paradigm BioCapital Advisors and Senai Asefaw, M.D. as reporting persons and shows specific share counts and ownership percentages as of March 31, 2026.
The statement reports 3,142,437 shares (3.8%) beneficially owned by Paradigm BioCapital Advisors (and affiliated GP/individual) and 2,769,062 shares (3.3%) held by Paradigm BioCapital International Fund Ltd. The filing cites 83,453,001 shares outstanding as of March 31, 2026 per the issuer's Form 10-Q filed May 7, 2026.
EyePoint, Inc. reported that an independent Data Safety Monitoring Committee completed its third scheduled review of the pivotal Phase 3 DURAVYU™ program for wet age-related macular degeneration and recommended that the LUGANO and LUCIA trials continue as planned with no protocol changes.
As of May 2, 2026, all active patients in the treatment arm had reached the Week 32 visit and received a second DURAVYU dose, with over 35% receiving a third dose at Week 56. Interim masked safety data show a continued favorable safety profile, consistent with experience in over 190 patients across four completed trials. The identical, aflibercept-controlled Phase 3 studies have enrolled over 900 patients, with topline wet AMD data expected beginning in mid-2026, while separate Phase 3 trials in diabetic macular edema are underway with data anticipated in the second half of 2027.
EyePoint, Inc. files an amended Schedule 13G/A reporting that Adage Capital Management and affiliated reporting persons beneficially own 3,300,000 shares of Common Stock, representing 3.96% of the class. The percentage is calculated using 83,431,950 shares outstanding as of February 27, 2026 per the company's Form 10-K.
The amendment attributes shared voting and dispositive power over the 3,300,000 shares to Adage entities and to named individuals Robert Atchinson and Phillip Gross; signatures by the reporting persons appear on the filing.
EyePoint, Inc. reported first-quarter 2026 results, combining heavier investment in its DURAVYU retinal franchise with a larger loss. Total revenue was $0.7 million, down from $24.5 million a year earlier, mainly because prior-year results included recognition of deferred license revenue from YUTIQ rights.
Operating expenses rose to $87.9 million from $73.3 million, driven by Phase 3 DURAVYU trials in wet AMD and DME and scaling its commercial manufacturing facility. EyePoint posted a net loss of $84.8 million, or ($0.99) per share, versus a $45.2 million loss, or ($0.65) per share, in 2025.
Cash, cash equivalents and marketable securities totaled $223 million as of March 31, 2026, down from $306 million on December 31, 2025. The company expects this cash to fund operations into the fourth quarter of 2027, beyond anticipated DURAVYU Phase 3 wet AMD milestones beginning mid-2026.
EyePoint, Inc. outlines strong 2025 execution and asks stockholders to act on key governance items at its virtual 2026 annual meeting. The company highlights rapid enrollment of over 900 patients in two Phase 3 LUGANO and LUCIA trials of DURAVYU for wet age-related macular degeneration and positive Phase 2 VERONA data in diabetic macular edema, with Phase 3 DME trials COMO and CAPRI underway. DURAVYU, a vorolanib intravitreal insert using Durasert E bioerodible technology, has shown no safety signals across more than 190 treated patients and has FDA‑conditionally accepted branding, though it remains investigational. Stockholders as of April 21, 2026 will vote on electing eight directors, approving Amendment No. 3 to the 2023 Long-Term Incentive Plan to add 4,900,000 shares, an advisory say-on-pay resolution, and ratification of Deloitte & Touche as independent auditor.
EyePoint, Inc. Chief Medical Officer Ramiro Ribeiro exercised stock options and sold the resulting shares in a same-day transaction. On April 17, 2026, he exercised options to acquire 2,437 shares of common stock at $8.26 per share, then sold 2,437 shares at $15.00 per share in an open-market sale.
Following these transactions, he reported no common stock held directly, while 80,438 stock options remained outstanding with an expiration date in 2035.
EYPT related Form 144: reported planned sale of 9,750 shares and recent 10b5-1 dispositions. The filing states 9,750 shares of Common stock are to be sold on 04/17/2026 in connection with an exercise of stock options for cash. It also lists prior 10b5-1 sales by Ramiro Ribeiro of 2,438 shares on 03/04/2026 (proceeds $43,571.69) and 2,437 shares on 02/17/2026 (proceeds $36,555.00).